Zai Lab's ``Ripatinib'' Chingle® was approved for domestic listing

0000pt;text-indent:22.

May 3 and then announced that Ding medicine, Chinese State Drug Administration has ( NMPA ) approved engine Lok ^® ® (erlotinib Swiss faction) listing application, has been used for the treatment received, including imatinib, including 3 species and more Adult patients with advanced gastrointestinal stromal tumor ( GIST ) treated with kinase inhibitors .

It is a mesenchymal tumor of the gastrointestinal tract, which is mainly caused by mutations of tyrosine kinase receptor ( KIT ) and platelet-derived growth factor receptor ( PDGFR α).

The onset is usually insidious and has no obvious specific symptoms.

It is reported that Repetinib was developed by Deciphera.
Zai Lab and Deciphera entered into an exclusive license agreement in June 2019.
According to this, Zai Lab obtained the exclusive license of certain patents and proprietary technologies from Deciphera for development and commercialization in the Greater China region.
Chemical products including Qingle® are used in the field of prevention, prevention, treatment, cure or alleviation of any human disease or disease.